NASDAQ:OTIC
Delisted
Otonomy Stock News
$0.0085
+0 (+0%)
At Close: Jul 11, 2023
Oppenheimer Sticks to Their Buy Rating for Otonomy (OTIC)
02:52pm, Wednesday, 18'th Mar 2020
Oppenheimer analyst Esther Rajavelu maintained a Buy rating on Otonomy (OTIC – Research Report) today. The company’s shares closed last
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) …
Easy Come, Easy Go: How Otonomy (NASDAQ:OTIC) Shareholders Got Unlucky And Saw 91% Of Their Cash Evaporate
07:53pm, Monday, 09'th Mar 2020
Otonomy, Inc. (NASDAQ:OTIC) shareholders should be happy to see the share price up 27% in the last quarter. But that...
Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
09:15pm, Thursday, 27'th Feb 2020
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fat
North Energy ASA : - Results for the fourth quarter 2019 | MarketScreener
06:30am, Thursday, 27'th Feb 2020Otonomy (OTIC) Reports Q4 Loss, Misses Revenue Estimates
12:00am, Thursday, 27'th Feb 2020Otonomy to Present at Two Upcoming Investor Conferences
12:30pm, Monday, 24'th Feb 2020
SAN DIEGO, Feb. 24, 2020 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
12:00am, Sunday, 23'rd Feb 2020Do Options Traders Know Something About Otonomy (OTIC) Stock We Don't?
12:00am, Friday, 21'st Feb 2020Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
12:30pm, Thursday, 20'th Feb 2020
SAN DIEGO, Feb. 20, 2020 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
Otonomy to Report Fourth Quarter and Full Year —…–9 Financial Results and Provide ...
12:00am, Thursday, 20'th Feb 202094 Biggest Movers From Yesterday
10:13am, Wednesday, 12'th Feb 2020
Gainers
Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) shares gained 78.5% to close at $3.66 after the company announced a license agreement with Zhejiang HaiChang Biotechnology....
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
12:30pm, Tuesday, 28'th Jan 2020
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collab
